CellVoyant Technologies Ltd – Trademark Portfolio
Entity Type: 98
CellVoyant Technologies Ltd holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 7 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include FATECAST, FATEVIEW, CELLVOYANT, IMPOSSIBLE TISSUES, and BETTER TISSUES, FASTER.
40 Berkeley Square
Bristol BS8 1HP
Showing of trademarks Trademarks
Trademark Classifications
CellVoyant Technologies Ltd's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does CellVoyant Technologies Ltd have?
CellVoyant Technologies Ltd has 7 U.S. trademarks filed with the USPTO. Of these, 7 registered.
What trademark classes does CellVoyant Technologies Ltd file in?
CellVoyant Technologies Ltd files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are CellVoyant Technologies Ltd's most well-known trademarks?
CellVoyant Technologies Ltd's registered trademark portfolio includes well-known marks such as FATECAST, FATEVIEW, CELLVOYANT, IMPOSSIBLE TISSUES, and BETTER TISSUES, FASTER. These are among 7 currently registered trademarks in the portfolio.
What is CellVoyant Technologies Ltd's trademark registration success rate?
CellVoyant Technologies Ltd has a 100% trademark registration rate, with 7 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.